We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




POC Hemometer Compared with Hematology Analyzer

By LabMedica International staff writers
Posted on 18 Apr 2019
The burden of anemia remains unacceptably high in sub-Saharan Africa. More...
It is linked to numerous life-threatening consequences like poor cognitive ability, diminished immunity and aggravated mortality.

To avert its effect, timely and accurate determination of hemoglobin concentration has been recognized. This has taken varied determination methods such as cyanmethemoglobin, use of copper II sulfate, automated hematology analyzers and point-of-care (POC) devices as the latest invention.

Medial Laboratory Scientists at Clarke International University (Kampala, Uganda) and their colleagues enrolled 402 participants, of these, 156 (38.8%) were male and 246 (61.2%) female. Participants had varied age categories, of whom 65 (16.2%) were 1 month–5 years, 42 (10.4%) were 5–11 years, 12 (3.0%) were 12–14 years, while 283 (70.4%) were 15 years and older. The average levels of Hb were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic participants, respectively.

Blood samples were assayed to estimate the hemoglobin (Hb) concentration using the TrueHb hemometer and Sysmex i3 hematology analyzer. Anemia was defined as Hb levels less than 11.0 g/dL, 11.5 g/dL and 12.0 g/dL for children aged 6–59 months, 5–11 years and 12–14 years, respectively. For adults, anemia was considered as Hb concentration less than 12.0 g/dL in non-pregnant women, 11.0 g/dL in pregnant women and 13.0 g/dL in males.

The team reported that the average Hb levels were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic patients, respectively. They found that 155 participants were anemic, giving an anemia prevalence of 38.6%. The mean difference of the TrueHb and Sysmex i3 assays was 2.222 ± 1.079, and the two devices did not show a difference in their measurements. Further, they showed a significant level of agreement and intraclass correlation coefficients. The sensitivity, specificity, positive and negative predictive values were 100 %, 51.01%, 55.16% and 100 %, respectively. The average performance turnaround time (TAT) for the TrueHb hemometer was 2.46 minutes.

The authors concluded that the TrueHb POC hemometer is an accurate POC for Hb estimation with a good performance agreement with the Sysmex i3 analyzer. This, coupled with its utility aspects, makes it a good diagnostic tool in a high anemia burden and low-resource setting. The study was published on April 1, 2019, in the Journal of Blood Medicine.

Related Links:
Clarke International University


New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Thyroid Test
Anti-Thyroid EIA Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.